1. The sixt Conference of the International Co-enzym coQ10 Association', Brussel, België 27 - 30 mei 2010.
2. Folkers K et al. Survival of cancer patiënts on therapy with co-enzym coQ10. Biochem Biophys Res Commun. 1993;192(1):241 - 5.
3. Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patiënts in relation to dosage of co-enzym coQ10. Biochem Biophys Res Commun. 1994;199(3):1504 - 8.
4. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in 'high risk' patiënts supplemented with nutritional antioxidants, essential fatty acids and co-enzym coQ10. Mol Aspects Med. 1994;15 Suppl:s231 - 40.
5. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin coQ10 and the regression of metastases. Biochem Biophys Res Commun 1995;212(1):172 - 7.
6. Folkers K. Relevance of the biosynthesis of co-enzym coQ10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun. 1996;224(2):358 - 61
7. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin coQ10 and the regression of metastases. Biochem Biophys Res Commun 1995;212(1):172 - 7
8. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin coQ10 in animal models and a serious deficiency in patiënts with cancer. Biochem Biophys Res Commun. 1997;234(2):296 - 9
9. Jolliet P et al. Plasma co-enzym coQ10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther. 1998 Sep;36(9):506 - 9.
10. Portakal O et al. Co-enzym coQ10 concentrations and antioxidant status in tissues of breast cancer patiënts. Clin Biochem. 2000 Jun;33(4):279 - 84.
11. Dhanasekaran M, et al. The emerging role of CoQ10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes. Curr Neurovasc Res. 2005 Dec;2(5):447 - 59.
12. Hertz N, Lister RE. Improved survival in patiënts with end-stage cancer treated with co-enzym Q(10) and other antioxidants: a pilot study. J Int Med Res 2009 Nov-Dec;37(6):1961 - 71.
13. Premkumar VG et al. Effect of co-enzym coQ10, riboflavin and niacin on serum CEA and CA 15 - 3 levels in breast cancer patiënts undergoing tamoxifen therapy. Biol Pharm Bull. 2007 Feb;30(2):367 - 70.
14. Premkumar VG et al. Anti-angiogenic potential of Co-enzymQ10, riboflavin and niacin in breast cancer patiënts undergoing tamoxifen therapy. Vascul Pharmacol. 2008 Apr-Jun;48(4 - 6):191 - 201.
15. Sachdanandam P. Antiangiogenic and hypolipidemic activity of co-enzym coQ10 supplementation to breast cancer patiënts undergoing Tamoxifen therapy. Biofactors 2008;32(1 - 4):151 - 9.
16. Premkumar VG, Sachdanandam P et al. Co-enzym coQ10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patiënts undergoing tamoxifen therapy. Br J Nutr. 2008 Dec;100(6):1179 - 82.
17. Yuvarai S et al. Effect of Co-enzym Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles. Breast Cancer res treat. 2009 Mar;114(2):377 - 84.
18. Premkumar VG, Sachdanandam P et al. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patiënts treated with tamoxifen and supplemented with co-enzym Q(10), riboflavin and niacin. Basic Clin Pharmacol Toxicol. 2007 Jun;100(6):387 - 91.
19. Yuvarai S, Premkumar VG, Sachdanandam P et al. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Co-enzym coQ10, Niacin and Riboflavin.Cancer Chemother Pharmacol 2008 May;61(6):933 - 41.
20. Quiles JL et al. Co-enzym Q differentially modulates phospholipid hydroperoxide glutathione peroxidase gene expression and free radicals production in malignant and non-malignant prostate cells. Biofactors. 2003;18(1 - 4):265 - 70.
21. Rusciani L et al. Recombinant interferon alpha-2b and co-enzym coQ10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.Melanoma Res. 2007 Jun;17(3):177 - 83.
22. Concklin KA. Co-enzym q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005 Jun;4(2):110 - 30.
23. Bryant et al. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1 - 84.
24. Desler C, Lykke A, Rasmussen LJ. The Effect of Mitochondrial Dysfunction on Cytosolic Nucleotide Metabolism. J Nucleic Acids. 2010 August 24; 2010: 701518. Published online
25. Bahar et al. Exogenous co-enzym coQ10 modulates MMP-2 activity in MCF-7 cell line as a breast cancer cellular model. Nutr J. 2010; 9: 62.
26. Pruimboom L. Cursus klinische PsychoNeuroimmunologie, 2e jaar. www.vannature.nl
27. Gellerich FN et al. Energetic depression caused by mitochondrial dysfunction. Mol Cell Biochem. 2004 Jan-Feb;256 - 257(1 - 2):391 - 405.
28. Nicolson GL. Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. Pathol Oncol Res. 2005;11(3):139 - 44
29. Perumal SS et al. Energy-modulating vitamins--a new combinatorial therapy prevents cancer cachexia in rat mammary carcinoma. Br J Nutr. 2005 Jun;93(6):901 - 9.
30. Nicolson GL, Conklin KA. Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Exp Metastasis. 2008;25(2):161 - 9.
31. Roffe L, Schmidt K, Ernst E. Efficacy of co-enzym coQ10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol. 2004 Nov 1;22(21):4418 - 24.
32. Nicolson GL. Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function. Cancer Metastasis Rev. 2010 Sep;29(3):543 - 52.
33. Chai W et al. Plasma co-enzym coQ10 levels and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2351 - 6